GSK joins Chai Discovery’s AI drug pipeline after wet-lab validation

Key points

• GSK signed an agreement with Chai Discovery to utilize its AI models for designing biologics, specifically antibodies.
• Chai Discovery is the sixth major pharma partner for the AI startup in the last nine months, joining a list that includes Eli Lilly, Bristol Myers Squibb, Novartis, and Pfizer.
• GSK conducted internal wet-lab tests on Chai’s designs, finding that the models generated binders for all tested targets with strong binding affinities.
• Chai’s latest model, Chai-3, is designed to achieve high success rates and binding affinities, including for challenging targets, building on the 16% hit rate of its previous model, Chai-2.
• GSK’s senior vice president of R&D technologies, Christopher Austin, stated that Chai’s technology complements GSK’s own internal models and helps accelerate medicine discovery.
• Chai Discovery raised a $400 million Series C funding round this year, reflecting investor confidence in its AI-enabled drug discovery platform.

Background

Chai Discovery has rapidly expanded its partnerships in 2026, signaling a shift in how large pharmaceutical companies are integrating AI into their R&D processes. The company’s progress has been documented in preprint papers, detailing the scientific capabilities of its models. GSK’s CEO, Luke Miels, previously emphasized that innovation is the top priority for AI usage in the company. This deal follows GSK’s recent $110 million agreement with AI-focused biotech Relation, which focuses on generating large-scale human cellular perturbation data. The broader trend reflects a growing reliance on AI for drug discovery, as seen in other sectors like the Chinese biopharma licensing boom.

How outlets are covering it

Endpoints News highlights the deal as Chai’s sixth pharma partnership in nine months, emphasizing the startup’s rapid growth and the initial pitch by founder Joshua Meier. Fierce Biotech provides detailed technical validation, noting that GSK’s wet-lab testing confirmed the AI-generated designs produced binders for all tested targets. Fierce Biotech also points out that while Chai has attracted major investors and partners, clinical validation is still pending. FirstWord Pharma’s content was inaccessible due to a JavaScript error, so no perspective could be extracted from that source. The outlets generally agree on the significance of the deal but differ in emphasis: Endpoints focuses on the business expansion, while Fierce Biotech focuses on the technical validation and the gap between AI promise and clinical reality.

Why it matters

The GSK-Chai Discovery deal underscores the increasing integration of AI in pharmaceutical R&D, particularly for biologics and antibody design. It signals that large pharma companies are moving beyond theoretical AI applications to validate and deploy AI-generated designs in wet-lab settings. This could accelerate the discovery of new medicines and reduce the time and cost associated with traditional drug development. However, the lack of clinical validation remains a key challenge, as the long timelines of drug development mean that the true impact of these AI models is yet to be seen. The deal also highlights the competitive landscape in AI-enabled drug discovery, with Chai Discovery securing major partnerships and significant funding.

What to watch

GSK and Chai Discovery will likely continue to collaborate on designing and testing new biologics, with GSK integrating Chai’s models into its internal R&D processes. Chai Discovery may seek additional partnerships and funding to expand its platform and validate its technology in clinical settings. The industry will watch for any clinical trials or pipeline advancements resulting from these AI-driven designs. GSK may also explore further AI collaborations, as indicated by its recent deal with Relation. The success or failure of these AI-generated designs in clinical trials will be a key indicator of the viability of AI in drug discovery.